Summary
Xenon Pharmaceuticals Inc (Xenon), formerly Xenon Genetics Inc is a clinical-stage bio-pharmaceutical company which discovers and develops differentiated therapeutics for orphan indications. The company's pipeline products comprises of Glybera, XEN801, XEN901, GDC-0310, and TV-45070. It discovers various validated drug targets through the study of rare human diseases with extreme traits, including channelopathies, diseases caused by mutations in ion channels. The company’s target treatment areas include lipoprotein lipase deficiency, cardiovascular diseases, dermatology, pain and dravet syndrome. It operates through partnerships with other drug development companies. Xenon is headquartered in Burnaby, British Columbia, Canada.
Xenon Pharmaceuticals Inc (XENE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Xenon Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 10
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Xenon Pharmaceuticals Acquires Development and Commercialization Rights for XEN1101 from 1st Order 12
Partnerships 13
Medpace Enters into Amendment Agreement with Xenon Pharma 13
Xenon Pharma Extends Agreement with Genentech 14
Licensing Agreements 15
Xenon Pharma Enters into Licensing Agreement with Pharma CMO 15
Xenon Pharma Exercises Option For Licensing Agreement With Isis Pharma For Antisense Drug XEN701 16
Merck Exercises Option For Licensing Agreement With Xenon Pharma For Cardiovascular Disease Targeted Compounds 18
Xenon Pharma Enters Into Licensing Agreement With Teva Pharma For XEN402 19
Xenon Pharma Extends Licensing Agreement with Genentech 20
Equity Offering 21
Xenon Pharma Completes Public Offering of Shares for USD34.5 Million 21
Xenon Pharma Raises USD41.4 Million in IPO of Shares 23
Xenon Pharmaceuticals Inc - Key Competitors 25
Xenon Pharmaceuticals Inc - Key Employees 26
Xenon Pharmaceuticals Inc - Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Financial Announcements 28
Aug 03, 2017: Xenon Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update 28
May 09, 2017: Xenon Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update 30
Mar 08, 2017: Xenon Pharmaceuticals Reports 2016 Financial Results and Provides Corporate Update 32
Nov 03, 2016: Xenon Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update 34
Aug 03, 2016: Xenon Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update 36
May 10, 2016: Xenon Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update 38
Mar 08, 2016: Xenon Pharmaceuticals Reports 2015 Financial Results and Provides Corporate Update 40
Corporate Communications 42
Sep 27, 2016: Xenon Pharmaceuticals Appoints Dawn Svoronos to Its Board of Directors 42
Product News 43
06/08/2016: Xenon Pharmaceuticals Presents Update on Nav1.6 Sodium Channel Inhibitor at the Jefferies 2016 Healthcare Conference 43
Clinical Trials 44
Jun 08, 2016: Xenon Pharmaceuticals Presents Corporate Update and Highlights Its Proprietary Therapeutic XEN801 Program at the Jefferies 2016 Healthcare Conference 44
Feb 10, 2016: Xenon Initiates Phase 2 Clinical Trial of XEN801 to Treat Moderate to Severe Acne 45
Other Significant Developments 46
Jan 08, 2017: Xenon Pharmaceuticals Outlines Key Milestones for 2017 46
Mar 31, 2016: Xenon Pharmaceuticals to Provide Business and Milestone Update at Needham Healthcare Conference 47
Jan 11, 2016: Xenon Outlines Key Milestones for 2016 48
Appendix 49
Methodology 49
About GlobalData 49
Contact Us 49
Disclaimer 49
List of Tables
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Xenon Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Xenon Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 10
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Xenon Pharmaceuticals Acquires Development and Commercialization Rights for XEN1101 from 1st Order 12
Medpace Enters into Amendment Agreement with Xenon Pharma 13
Xenon Pharma Extends Agreement with Genentech 14
Xenon Pharma Enters into Licensing Agreement with Pharma CMO 15
Xenon Pharma Exercises Option For Licensing Agreement With Isis Pharma For Antisense Drug XEN701 16
Merck Exercises Option For Licensing Agreement With Xenon Pharma For Cardiovascular Disease Targeted Compounds 18
Xenon Pharma Enters Into Licensing Agreement With Teva Pharma For XEN402 19
Xenon Pharma Extends Licensing Agreement with Genentech 20
Xenon Pharma Completes Public Offering of Shares for USD34.5 Million 21
Xenon Pharma Raises USD41.4 Million in IPO of Shares 23
Xenon Pharmaceuticals Inc, Key Competitors 25
Xenon Pharmaceuticals Inc, Key Employees 26
Xenon Pharmaceuticals Inc, Subsidiaries 27
List of Figures
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Xenon Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 10
